Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R known ✓ | P07333 | 16/20 | 1.00 |
| ▸ | EGFR known ✓ | P00533 | 16/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.73 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.73 |
| ▸ | KIF5B | P33176 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2257706 | 0.99 | CSF1R (1.00) | CSF1REGFRPDGFRBPDGFRARET | |
| SCHEMBL18158260 | 0.89 | CSF1R (0.81) | CSF1REGFRPDGFRBPDGFRARET | |
| Hydrochloric Acid SCHEMBL6180936 | 0.88 | CSF1R (1.00) | CSF1REGFRPDGFRBPDGFRARET | |
| Hydrochloric Acid SCHEMBL6180769 | 0.88 | CSF1R (0.81) | CSF1REGFRPDGFRBPDGFRARET | |
| Hydrochloric Acid SCHEMBL6179893 | 0.86 | CSF1R (1.00) | CSF1REGFRPDGFRBPDGFRARET | |
| SCHEMBL6183306 | 0.86 | CSF1R (1.00) | CSF1REGFRPDGFRBPDGFRARET | |
| SCHEMBL6181267 | 0.86 | CSF1R (0.80) | CSF1REGFRPDGFRBPDGFRARET | |
| Hydrochloric Acid SCHEMBL6180093 | 0.86 | EGFR (1.00) | CSF1REGFRPDGFRBPDGFRARET | |
| SCHEMBL6180768 | 0.85 | CSF1R (1.00) | CSF1REGFRPDGFRBPDGFRARET | |
| SCHEMBL6181700 | 0.84 | EGFR (1.00) | CSF1REGFRPDGFRBPDGFRARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0871448-B1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | AVENTIS PHARMA INC (US) | 2005-03-02 | — | — | EP | claimed |
| US-20040014774-A1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | AVENTIS PHARMACEUTICALS INC. | 2004-01-22 | — | — | US | claimed |
| EP-0871448-A4 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE POULENC RORER PHARMA (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0871448-A1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-10-21 | — | — | EP | claimed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | claimed |
| WO-1995015758-A1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-06-15 | — | — | WO | claimed |
| EP-0871448-B1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | AVENTIS PHARMA INC (US) | 2005-03-02 | — | — | EP | disclosed |
| EP-1488792-A2 | Quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | Aventis Pharmaceuticals Products Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040014774-A1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | AVENTIS PHARMACEUTICALS INC. | 2004-01-22 | — | — | US | disclosed |
| US-6645969-B1 | Antiproliferative, anticarcinogenic, and antiinflammatory agents; treatment of leukemia, psoriasis, bone disorders, and atherosclerosis | AVENTIS PHARMACEUTICALS INC. | 2003-11-11 | — | — | US | disclosed |
| US-RE37650-E1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | AVENTIS PHARMACETICAL PRODUCTS, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-0871448-A4 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE POULENC RORER PHARMA (US) | 1999-12-29 | — | — | EP | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5721237-A | ADMINISTERING FOR THE SELECTIVE TREATMENT OF CELL GROWTH AND DIFFERENTIATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-24 | — | — | US | disclosed |
| US-5714493-A | ANTIINFLAMMATORY AGENT | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5710158-A | INHIBITORS OF PROTEIN TYROSINE KINASE AND EPIDERMAL GROWTH FACTOR | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-01-20 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1996039145-A1 | PROTEIN TYROSINE KINASE ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS HAVING SELECTIVE INHIBITION OF HER-2 AUTOPHOSPHORYLATION PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| WO-1995015758-A1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014774-A1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | CSF1R, CSF3R, FLT3 | CSF1R 1/4885EGFR 628/4885PDGFRB 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.